U.S. Life Sciences Stock News

On August 19, 2025, Geoscience Australia and Toitū Te Whenua Land Information New Zealand announced a A$252 million expansion contract with Viasat to provide additional satellite services for the Southern Positioning Augmentation Network (SouthPAN) across Australia and New Zealand. This development significantly extends Viasat's government partnerships in the region and reinforces its influence in delivering crucial satellite-enabled positioning and navigation services for a range of...

Earlier this week, DHT Holdings reported enhanced operational efficiency and a stronger focus on time charter agreements to stabilize costs and margins, highlighting continued resilience in a shifting shipping market. An increased emphasis on time charters over spot rates, along with prudent debt management and robust free cash flow, is aimed at supporting stable returns for shareholders. We'll examine how DHT's shift toward stable time charter contracts may influence its long-term earnings...

Carvana (CVNA) quietly edged up yesterday, continuing a trend that has drawn fresh attention from investors weighing their next move. The latest tick might look minor at first glance, but in a market where momentum can shift quickly, even slight changes like this can prompt questions: Is this the beginning of something bigger, or simply noise? For many shareholders, these moves spark debate about Carvana’s underlying value and what the coming months could hold. Taking a step back, Carvana’s...

Fiserv (FI) saw its shares slip a bit further this week, a move that might leave some investors scratching their heads in the absence of any headline-grabbing news. There are no big announcements or dramatic shifts in company strategy driving the recent price change. When a consistent slide like this occurs, it often prompts people to wonder whether the market is picking up on something deeper in the company’s outlook. Sometimes, it is moments like these—without a clear trigger—that can offer...

If you have been wondering what to do with Gen Digital stock, you are not alone. Investors are sizing up whether this cybersecurity software company is set for another run or if it has already had its moment. The stock has seen a healthy boost of 25% over the past year and more than 43% over five years, a sign that perceived risk is easing and growth momentum is building. Gen Digital recently closed at $31.19, with analysts putting the price target around $33.72. This represents an 8%...

J.B. Hunt Transport Services recently announced the appointment of Brad Delco as Chief Financial Officer and Executive Vice President of Finance, effective September 1, 2025, after his extensive roles overseeing finance and investor relations since joining the company in 2019. Delco’s experience in corporate development, environmental and governance strategy, and transportation sector financial management positions him to influence the company's strategic direction. We'll consider how...

In August 2025, EQT Corporation closed a shelf registration, issuing 25,229,166 shares of common stock for a total value of US$1.27 billion, while EQT AB repurchased 497,182 of its own shares as part of a broader buyback program. The combination of issuing new shares and executing a share repurchase program highlights EQT’s dual focus on capital raising and capital management initiatives. We’ll now assess how EQT’s capital actions, particularly the large-scale share issuance, may shape its...

Campbell's and Pabst Blue Ribbon recently introduced two beer-infused soups, available exclusively at Walmart starting August 2025, with the launch promoted through a dive bar event in New York City and a nationwide Walmart food truck tour. This unique collaboration combines two iconic brands and leverages experiential marketing to generate consumer interest and excitement within the packaged food sector. We'll now explore how this product launch and marketing strategy with Pabst Blue Ribbon...

The Andersons, Inc. declared a fourth quarter 2025 cash dividend of US$0.195 per share, payable on October 22, 2025, and recently announced the appointments of Steven Oakland to its board and Emmanuel Ayuk as executive vice president, general counsel, and corporate secretary. These leadership additions bring significant food and agriculture industry expertise and governance experience to Andersons, potentially impacting its future strategic direction and operational oversight. We'll explore...

Thinking about whether to buy, hold, or even sell Spotify Technology stock? You are not alone. With all the noise in streaming and tech stocks lately, Spotify stands out as a company that keeps investors asking what comes next. Over the past year, Spotify's share price has soared more than 100%, fueled by impressive annual revenue growth just over 11% and even more dramatic growth in net income. Even short-term movements have been upbeat, with the stock up more than 5% in the last three...

Sunshine Retirement Living recently announced a management agreement with Sabra Health Care REIT to oversee five independent living communities in Arizona, California, Utah, and Washington, growing Sunshine’s portfolio from 35 to 40 communities. This partnership signifies Sunshine's expansion into third-party management for the first time, reflecting broader shifts in the senior housing industry as the over-85 population rises. Let’s examine how this expanded management arrangement could...

The yearly results for The Estée Lauder Companies Inc. ( NYSE:EL ) were released last week, making it a good time to...

Wondering what to make of Veeva Systems stock right now? You are not alone. If you have been watching Veeva over the last year, you have seen some eye-catching numbers. The stock has climbed more than 43% in the past 12 months, with much of that growth accelerating in the past quarter. Investors who have stuck with Veeva saw a 21% jump over just the last 90 days, showing that momentum is strong, even after some dips earlier this year. So what is driving these moves? Part of it is Veeva’s...

Earlier this month, Schrödinger, Inc. announced it has ended the clinical development program for SGR-2921, its CDC7 inhibitor, following two patient deaths linked to the drug in a Phase 1 trial for acute myeloid leukemia and high-risk myelodysplastic syndromes. Although preclinical and early trial data suggested potential, Schrödinger determined further development would be too challenging due to emerging safety concerns. We’ll examine how the discontinuation of SGR-2921 due to safety...

ConocoPhillips Skandinavia AS recently awarded Halliburton a major five-year contract for comprehensive well stimulation services, including the transformation of the North Pomor vessel in the North Sea and implementation of Octiv digital fracturing technology. This contract highlights Halliburton's technological strengths in offshore stimulation and its ability to deliver integrated solutions for complex international projects. We'll now explore how this significant contract win supports...

Analog Devices ( NASDAQ:ADI ) Third Quarter 2025 Results Key Financial Results Revenue: US$2.88b (up 25% from 3Q 2024...

DLocal recently reported second-quarter and first-half 2025 earnings with revenue for the quarter rising to US$256.46 million and the company updating full-year guidance to anticipate 30%-40% annual growth, while also announcing the appointment of Guillermo López Pérez as Chief Financial Officer. The combination of robust revenue figures, improved multi-period profitability, and top leadership changes highlights a period of strong operational progress and ongoing focus on governance at...

Trying to decide what to do with Martin Marietta Materials stock? You are not alone. Whether you have been following the aggregates giant for years or are just now giving MLM a closer look, its price movements this year make it a hot topic for investors focused on growth and value. This stock has been far from stagnant. Over the past year, it has delivered a total return of 11.4%, with notable momentum in just the past month, up 5.2%. Even more impressive, its five-year return tops 197%,...

Dynavax Technologies (DVAX) just shook up the vaccine landscape with positive topline data from its initial Phase 1/2 trial of Z-1018, a new shingles vaccine candidate. The headline here is parity: Z-1018 generated immune responses similar to Shingrix, the leading shingles shot, but with fewer moderate or severe side effects. With plans to kick off studies in older adults soon, the company is signaling confidence in its pipeline and putting itself in direct competition with established...

If you’ve been watching MPLX (MPLX), you’re probably noticing a subtle uptick in attention as the stock sits near its all-time highs with little headline news to drive it. Sometimes, a calm market move raises even more questions. Could steady performance signal confidence in MPLX’s outlook, or are investors simply waiting for the next catalyst? Either way, small gains in the background can often say as much as a dramatic headline moment. Over the past year, MPLX shares have delivered a 29%...

If you are looking at Southern’s latest share price and wondering whether now is the moment to act, you are not alone. The company’s stock has moved around quite a bit in recent months, offering both optimism and a bit of intrigue for investors considering their next steps. Over the past quarter, Southern has risen about 5.6%, and if you zoom out further, this year’s total return is comfortably above 15%, with a 119% return over the last five years. Not many utility companies can claim that...

If you are on the fence about what to do with Walt Disney stock, you are far from alone. The last year has been a bit of a rollercoaster for DIS, but the ride may be more about what lies ahead than what is in the rearview mirror. Disney’s share price has climbed more than 30% over the past year, outpacing the broader market and sparking optimism about a turnaround. Still, that short-term boost follows a far less inspiring three-year picture and a negative five-year return. This serves as a...

Earlier this week, Daiichi Sankyo and Merck announced that ifinatamab deruxtecan received Breakthrough Therapy Designation from the U.S. FDA for adults with extensive-stage small cell lung cancer who have progressed after platinum-based chemotherapy, based on promising early clinical data. This marks the first Breakthrough Therapy Designation for ifinatamab deruxtecan, accelerating its development and highlighting its potential to address an unmet need in oncology. Now, we’ll consider how...

The analysts might have been a bit too bullish on ZIM Integrated Shipping Services Ltd. ( NYSE:ZIM ), given that the...